The Journal of Maternal-Fetal Medicine · 2000 · 60 citations · 17 references
MedicineMaternal HealthObstetricsBone MetabolismMaternal-fetal MedicineMineral MetabolismBone Density RegulationBone GrowthBone HealthBone Metabolism DisordersOsteoporosisPregnancyBone Mass AcquisitionBone Mass GainDrug Effects On Bone DensityLow Bone MassLow Bone Mineral DensityMaternal Bone Health
OBJECTIVE: To evaluate changes in bone density in women receiving enoxaparin sodium during pregnancy. METHODS: Bone density in the proximal femur was serially measured in 16 women receiving enoxaparin sodium (40 mg daily) during pregnancy. Baseline measurements were taken within 2 weeks of starting therapy and then at 6-8 weeks postpartum and 6 months postpartum. RESULTS: Patients received enoxaparin sodium for a mean duration of 25 weeks (range, 19-32 weeks). There was no significant change in mean bone density measurement from baseline measurements to the conclusion of therapy at 6 weeks postpartum and no patient experienced a decrease in bone mass of >10% at 6 weeks postpartum. By 6 months postpartum, there was a significant mean decrease in bone density (P = 0.02) and two of the 14 patients evaluated (14%) experienced an overall bone loss of >10%. CONCLUSION: The prolonged used of enoxaparin sodium may not cause significant bone loss during pregnancy.
17
Catherine Nelson‐Piercy, Elizabeth A. Letsky, Michael de Swiet · American Journal of Obstetrics and Gynecology · 1997 · 268 citations
Medicine, Gynecology, Obstetrics +17